Nature Communications (Oct 2022)

Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma

  • William H. Tomaszewski,
  • Jessica Waibl-Polania,
  • Molly Chakraborty,
  • Jonathan Perera,
  • Jeremy Ratiu,
  • Alexandra Miggelbrink,
  • Donald P. McDonnell,
  • Mustafa Khasraw,
  • David M. Ashley,
  • Peter E. Fecci,
  • Luigi Racioppi,
  • Luis Sanchez-Perez,
  • Michael D. Gunn,
  • John H. Sampson

DOI
https://doi.org/10.1038/s41467-022-34175-y
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 17

Abstract

Read online

Responses to immune checkpoint blockade (ICB) in patients with glioblastoma are limited. Here the authors show that Calmodulin-Dependent Kinase Kinase 2 (CaMKK2) is expressed in tumor associated macrophages and neurons and is associated with resistance to ICB in preclinical models of glioblastoma.